RS58793B1 - Selektivni inhibitori pi3k delta - Google Patents

Selektivni inhibitori pi3k delta

Info

Publication number: RS58793B1
Authority: RS; Serbia
Prior art keywords: pi3k delta; delta inhibitors; selective pi3k; selective; inhibitors
Prior art date: 2012-07-04

Application number

RS20190687A

Other languages

English (en)

Inventor

Swaroop Kumar Venkata Satya Vakkalanka

Meyyappan Muthuppalaniappan

Dhanapalan Nagarathnam

Original Assignee

Rhizen Pharmaceuticals S A

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-07-04

Filing date

2013-07-02

Publication date

2019-07-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54193752&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS58793(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-07-02 Application filed by Rhizen Pharmaceuticals S A filed Critical Rhizen Pharmaceuticals S A

2019-07-31 Publication of RS58793B1 publication Critical patent/RS58793B1/sr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/14—Ectoparasiticides, e.g. scabicides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
- C12Y207/01137—Phosphatidylinositol 3-kinase (2.7.1.137)
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Diabetes (AREA)
Immunology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Oncology (AREA)
Obesity (AREA)
Gynecology & Obstetrics (AREA)
Heart & Thoracic Surgery (AREA)

RS20190687A 2012-07-04 2013-07-02 Selektivni inhibitori pi3k delta RS58793B1 (sr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
IN2693CH2012		2012-07-04
IN2692CH2012		2012-07-04
US201261691586P	2012-08-21	2012-08-21
US201261691561P	2012-08-21	2012-08-21
EP17181585.5A EP3260455B1 (en)	2012-07-04	2013-07-02	Selective pi3k delta inhibitors

Publications (1)

Publication Number	Publication Date
RS58793B1 true RS58793B1 (sr)	2019-07-31

Family

ID=54193752

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
RS20190687A RS58793B1 (sr)	2012-07-04	2013-07-02	Selektivni inhibitori pi3k delta
RS20171141A RS56494B1 (sr)	2012-07-04	2013-07-02	Selektivni inhibitori pi3k delta

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
RS20171141A RS56494B1 (sr)	2012-07-04	2013-07-02	Selektivni inhibitori pi3k delta

Country Status (33)

Country	Link
US (7)	US9150579B2 (sr)
EP (2)	EP2870157B1 (sr)
JP (2)	JP6181173B2 (sr)
KR (2)	KR101988079B1 (sr)
CN (2)	CN109970742A (sr)
AP (1)	AP2015008207A0 (sr)
AR (1)	AR091677A1 (sr)
AU (1)	AU2013285081B2 (sr)
BR (1)	BR112014033055B1 (sr)
CA (1)	CA2876995C (sr)
CL (1)	CL2014003511A1 (sr)
CO (1)	CO7170166A2 (sr)
CY (2)	CY1119588T1 (sr)
DK (2)	DK2870157T3 (sr)
EA (1)	EA028750B1 (sr)
ES (1)	ES2647416T3 (sr)
HK (1)	HK1209737A1 (sr)
HR (1)	HRP20171610T1 (sr)
HU (1)	HUE034591T2 (sr)
IL (1)	IL236351B (sr)
LT (2)	LT3260455T (sr)
MX (1)	MX357043B (sr)
MY (1)	MY169987A (sr)
PH (2)	PH12014502865B1 (sr)
PL (2)	PL2870157T3 (sr)
PT (1)	PT2870157T (sr)
RS (2)	RS58793B1 (sr)
SG (2)	SG10201704048UA (sr)
SI (2)	SI3260455T1 (sr)
SM (2)	SMT201900334T1 (sr)
TW (1)	TWI598100B (sr)
WO (1)	WO2014006572A1 (sr)
ZA (2)	ZA201409329B (sr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA036876B1 (ru)	2009-11-05	2020-12-30	Ризен Фармасьютикалз С.А.	Ингибиторы pi3k киназы
BR112013027774B1 (pt)	2011-05-04	2020-11-17	Rhizen Pharmaceuticals S.A.	composto e composição farmacêutica
US10130635B2 (en)	2012-05-04	2018-11-20	Rhizen Pharmaceuticals Sa	Process for preparation of optically pure and optionally substituted 2-(1-hydroxy-alkyl)-chromen-4-one derivatives and their use in preparing pharmaceuticals
AP3547A (en) *	2012-05-04	2016-01-14	Rhizen Pharmaceuticals Sa	Process for preparation of optically pure and optionally substituted 2- (1 -hydroxy- alkyl) - chromen - 4 - one derivatives and their use in preparing pharmaceuticals
DK2870157T3 (da) *	2012-07-04	2017-11-06	Rhizen Pharmaceuticals S A	Selektive pi3k delta-hæmmere
SG10201704511RA (en) *	2012-11-02	2017-07-28	Tg Therapeutics Inc	Combination of anti-cd20 antibody and pi3 kinase selective inhibitor
CA2914284A1 (en)	2013-05-30	2014-12-04	Infinity Pharmaceuticals, Inc.	Treatment of cancers using pi3 kinase isoform modulators
PT3119397T (pt)	2014-03-19	2022-04-11	Infinity Pharmaceuticals Inc	Compostos heterocíclicos para utilização no tratamento de distúrbios mediados por pi3k-gama
US20150320754A1 (en)	2014-04-16	2015-11-12	Infinity Pharmaceuticals, Inc.	Combination therapies
WO2015160975A2 (en)	2014-04-16	2015-10-22	Infinity Pharmaceuticals, Inc.	Combination therapies
ES2880999T3 (es) *	2014-05-27	2021-11-26	Rhizen Pharmaceuticals S A	Sal de tosilato cristalina de un inhibidor selectivo de PI3K delta para uso en formulaciones farmacéuticas
ES2708748T3 (es) *	2014-06-27	2019-04-11	Rhizen Pharmaceuticals S A	Derivados de cromeno sustituidos como inhibidores duales selectivos de proteína cinasas PI3 delta y gamma
EA201692557A1 (ru)	2014-07-04	2017-05-31	Люпин Лимитед	Хинолизиноновые производные в качестве ингибиторов pi3k
WO2016054491A1 (en)	2014-10-03	2016-04-07	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
US20190070183A1 (en) *	2015-11-04	2019-03-07	The Trustees Of Columbia University In The City Of New York	Targeting Casein Kinase-1 and PI3K/AKT/mTOR Pathways for Treatment of c-Myc-Overexpressing Cancers, Organ Transplant Associated Complications and Autoimmune Diseases
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
US10941136B2 (en)	2016-04-29	2021-03-09	Yuhan Corporation	Quinazoline derivative or its salt and pharmaceutical composition comprising the same
US10966977B2 (en)	2016-05-27	2021-04-06	Tg Therapeutics, Inc.	Combination of anti-CD20 antibody, P13 kinase-delta selective inhibitor, and BTK inhibitor to treat b-cell proliferative disorders
US10919914B2 (en)	2016-06-08	2021-02-16	Infinity Pharmaceuticals, Inc.	Heterocyclic compounds and uses thereof
KR20190033526A (ko)	2016-06-24	2019-03-29	인피니티 파마슈티칼스, 인코포레이티드	병용 요법
WO2018002958A1 (en)	2016-06-30	2018-01-04	Sun Pharma Advanced Research Company Limited	Novel hydrazide containing compounds as btk inhibitors
AU2017322501A1 (en)	2016-09-09	2019-03-28	Laboratoire Francais Du Fractionnement Et Des Biotechnologies	Combination of an anti-CD20 antibody, PI3 kinase-delta inhibitor, and anti-PD-1 or anti-PD-L1 antibody for treating hematological cancers
US11040033B2 (en)	2017-08-22	2021-06-22	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
CN108434150B (zh) *	2018-02-09	2020-03-10	天津医科大学总医院	Zstk474用于制备ean治疗药物的应用
AU2019297362B2 (en)	2018-07-06	2022-05-26	Gilead Sciences, Inc.	Therapeutic heterocyclic compounds
CN112384283B (zh)	2018-07-06	2023-08-15	吉利德科学公司	治疗性的杂环化合物
JP2021535907A (ja) *	2018-08-21	2021-12-23	南京明徳新薬研発有限公司	ピラゾロピリミジン誘導体及びそのｐｉ３ｋ抑制剤とする適用
EP3964512A4 (en) *	2019-06-27	2022-08-10	Hangzhou Healzen Therapeutics Co., Ltd.	CASEINKINASE-1-EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND ITS USE
BR112022000684A2 (pt)	2019-07-15	2022-03-03	Johnson Matthey Plc	Monotosilato de umbralisibe, processo para preparar uma forma amorfa, forma amorfa de monotosilato de umbralisibe, composição farmacêutica, e, método de tratamento de doença
WO2021164789A1 (zh) *	2020-02-21	2021-08-26	南京明德新药研发有限公司	一种吡唑并嘧啶类化合物的晶型及其应用
US20220143026A1 (en)	2020-11-12	2022-05-12	Tg Therapeutics, Inc.	Triple combination to treat b-cell malignancies
CN114891005B (zh) *	2022-03-30	2024-01-19	武汉九州钰民医药科技有限公司	一种乌帕利斯对甲苯磺酸盐的制备工艺
US11884740B1 (en)	2022-06-01	2024-01-30	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11965032B1 (en)	2022-06-01	2024-04-23	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11807689B1 (en)	2022-06-01	2023-11-07	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions
US11814439B1 (en)	2022-06-01	2023-11-14	Tg Therapeutics, Inc.	Anti-CD20 antibody compositions

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS62201882A (ja)	1985-11-18	1987-09-05	Yamanouchi Pharmaceut Co Ltd	イソフラボン誘導体
JPH08175990A (ja)	1994-12-19	1996-07-09	Mitsubishi Chem Corp	Ｐｉ３キナーゼ阻害剤とその製造法
JPH08176070A (ja)	1994-12-19	1996-07-09	Mitsubishi Chem Corp	ジデプシド誘導体及びｐｉ３キナーゼ阻害剤
GB9521987D0 (en)	1995-10-26	1996-01-03	Ludwig Inst Cancer Res	Phosphoinositide 3-kinase modulators
JP2001247477A (ja)	2000-03-03	2001-09-11	Teikoku Hormone Mfg Co Ltd	抗腫瘍剤
HU230554B1 (hu)	2000-04-25	2016-12-28	Icos Corporation	Humán foszfatidilinozit-3-kináz-delta inhibitorok és alkalmazásuk
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
US6403588B1 (en)	2000-04-27	2002-06-11	Yamanouchi Pharmaceutical Co., Ltd.	Imidazopyridine derivatives
JP4458746B2 (ja)	2001-01-16	2010-04-28	グラクソグループリミテッド	癌の治療方法
US20040242545A1 (en)	2001-07-26	2004-12-02	Santen Phamaceutical Co., Ltd.	Remedy for glaucoma comprising as the active ingredient compound having p13 kinase inhibitory effect
US6703414B2 (en)	2001-09-14	2004-03-09	Arizona Board Of Regents On Behalf Of The University Of Arizona	Device and method for treating restenosis
AU2002349912A1 (en)	2001-10-24	2003-05-06	Iconix Pharmaceuticals, Inc.	Modulators of phosphoinositide 3-kinase
WO2003034997A2 (en)	2001-10-24	2003-05-01	Iconix Pharmaceuticals, Inc.	Modulators of phosphoinositide 3-kinase
CA2464924A1 (en)	2001-10-30	2003-05-08	Pharmacia Corporation	Heteroaromatic carboxamide derivatives for the treatment of inflammation
JP4664597B2 (ja) *	2002-04-17	2011-04-06	サイトキネティクス・インコーポレーテッド	化合物、組成物および方法
US20040092561A1 (en)	2002-11-07	2004-05-13	Thomas Ruckle	Azolidinone-vinyl fused -benzene derivatives
JP2006500327A (ja)	2002-07-10	2006-01-05	アプライドリサーチシステムズエーアールエスホールディングナームロゼフェンノートシャップ	精子の運動性を増大させるための化合物の使用
PL374718A1 (en)	2002-07-10	2005-10-31	Applied Research Systems Ars Holding N.V.	Azolidinone-vinyl fused-benzene derivatives
WO2004017950A2 (en)	2002-08-22	2004-03-04	Piramed Limited	Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US7601724B2 (en)	2002-09-04	2009-10-13	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
US7605155B2 (en)	2002-09-04	2009-10-20	Schering Corporation	Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
EP2289936B1 (en)	2002-12-16	2017-05-31	Genentech, Inc.	Immunoglobulin variants and uses thereof
WO2004072029A2 (en)	2003-02-06	2004-08-26	Vertex Pharmaceuticals Incorporated	Pyrazolopyridazines useful as inhibitors of protein kinases
WO2004096135A2 (en)	2003-04-24	2004-11-11	Merck & Co., Inc.	Inhibitors of akt activity
AU2004263148B2 (en)	2003-08-06	2008-08-21	Vertex Pharmaceuticals, Incorporated	Aminotriazole compounds useful as inhibitors of protein kinases
US7501427B2 (en)	2003-08-14	2009-03-10	Array Biopharma, Inc.	Quinazoline analogs as receptor tyrosine kinase inhibitors
US20050043239A1 (en)	2003-08-14	2005-02-24	Jason Douangpanya	Methods of inhibiting immune responses stimulated by an endogenous factor
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
JP2008514628A (ja)	2004-09-24	2008-05-08	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	蛋白質キナーゼ類のイミダゾ｛４，５−ｂ｝ピラジノン阻害剤
GB0423653D0 (en)	2004-10-25	2004-11-24	Piramed Ltd	Pharmaceutical compounds
MY179032A (en)	2004-10-25	2020-10-26	Cancer Research Tech Ltd	Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
FR2882751B1 (fr)	2005-03-04	2007-09-14	Aventis Pharma Sa	Hydrazinocarbonyl-thieno[2,3-c]pyrazoles, procede de preparation, compositions les contenant et utilisation
US20090258852A1 (en)	2005-07-08	2009-10-15	Arrington Kenneth L	Inhibitors of Checkpoint Kinases
BRPI0614578A2 (pt)	2005-08-16	2011-04-05	Irm Llc	composto, composição farmacêutica como inibidores de proteìna cinases, bem como seu método e uso
US7595330B2 (en)	2005-09-06	2009-09-29	Smithkline Beecham Corporation	Benzimidazole thiophene compounds
GEP20115304B (en)	2005-10-07	2011-10-10	Exelixis Inc	PYRIDOPYRIMIDINONE INHIBITORS OF PI3Kα
GB0520657D0 (en)	2005-10-11	2005-11-16	Ludwig Inst Cancer Res	Pharmaceutical compounds
US7790739B2 (en)	2005-10-21	2010-09-07	Merck & Co., Inc. and Merck Sharp & Dohme Corp.	Tyrosine kinase inhibitors
WO2007084391A2 (en)	2006-01-18	2007-07-26	Amgen Inc.	Thiazole compounds as protein kinase b ( pkb) inhibitors
WO2007099317A1 (en)	2006-03-02	2007-09-07	Astrazeneca Ab	Quinazoline derivatives
EP1999135A2 (en)	2006-03-30	2008-12-10	Takeda San Diego, Inc.	Kinase inhibitors
AU2007243466B2 (en)	2006-04-26	2012-01-19	F. Hoffmann-La Roche Ag	Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
RS51401B (sr)	2006-04-26	2011-02-28	F.Hoffmann-La Roche Ag	Tieno[3,2-d]pirimidinski derivat koji je koristan kao inhibitor p13k
JPWO2007132867A1 (ja)	2006-05-15	2009-09-24	杉本　芳一	癌の予防及び治療剤
GB0610243D0 (en)	2006-05-23	2006-07-05	Novartis Ag	Organic compounds
JP2009543768A (ja)	2006-07-14	2009-12-10	アステックス・セラピューティクス・リミテッド	医薬組み合わせ
US7605160B2 (en)	2006-08-09	2009-10-20	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
JP2010503650A (ja)	2006-09-14	2010-02-04	アストラゼネカアクチボラグ	増殖性疾患の治療のための、ｐｉ３ｋおよびｍｔｏｒ阻害剤としての２−ベンズイミダゾリル−６−モルホリノ−４−ピペリジン−４−イルピリミジン誘導体
TWI499420B (zh)	2006-12-07	2015-09-11	Hoffmann La Roche	肌醇磷脂３-激酶抑制劑化合物及使用方法
ES2571028T3 (es) *	2006-12-07	2016-05-23	Genentech Inc	Compuestos inhibidores de fosfoinositida 3-cinasa y métodos de uso
JP2010526823A (ja)	2007-05-10	2010-08-05	グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー	Ｐｉ３キナーゼ阻害物質としてのキノキサリン誘導体
US20090263397A1 (en)	2007-07-06	2009-10-22	Buck Elizabeth A	Combination anti-cancer therapy
ATE551342T1 (de)	2008-02-22	2012-04-15	Irm Llc	Heterocyclische verbindungen und zusammensetzungen als c-kit- und pdgfr- kinasehemmer
WO2009108912A1 (en)	2008-02-29	2009-09-03	Cylene Pharmaceuticals, Inc.	Protein kinase modulators
US20090227575A1 (en)	2008-03-04	2009-09-10	Wyeth	7H-PYRROLO[2,3-H]QUINAZOLINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESIS
MX2010009401A (es)	2008-03-04	2010-09-24	Natco Pharma Ltd	Forma cristalina de derivado de fenilamino pirimidina.
WO2009111531A1 (en)	2008-03-06	2009-09-11	Bristol-Myers Squibb Company	Pyrrolotriazine kinase inhibitors
UY31700A (es)	2008-03-13	2009-11-10	Boehringer Ingelheim Int	Tiazolil-dihidro-indazoles
WO2009114874A2 (en) *	2008-03-14	2009-09-17	Intellikine, Inc.	Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja)	2008-03-14	2014-07-09	インテリカイン，エルエルシー	キナーゼ阻害剤および使用方法
US8268834B2 (en)	2008-03-19	2012-09-18	Novartis Ag	Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
AU2009225614A1 (en)	2008-03-19	2009-09-24	Osi Pharmaceuticals, Inc	mTOR inhibitor salt forms
EP2262807B1 (en)	2008-03-19	2015-08-12	ChemBridge Corporation	Novel tyrosine kinase inhibitors
US20110053907A1 (en)	2008-03-27	2011-03-03	Auckland Uniservices Limited	Substituted pyrimidines and triazines and their use in cancer therapy
CA2719032C (en)	2008-03-31	2016-11-08	Steven Do	Benzopyran and benzoxepin pi3k inhibitor compounds and methods of use
US20090258907A1 (en)	2008-04-09	2009-10-15	Abbott Laboratories	Compounds useful as inhibitors of rock kinases
EP2297145A2 (en)	2008-04-16	2011-03-23	Takeda Pharmaceutical Company Limited	Polymorphs of 5-(3-(ethylsulfonyl)phenyl)-3,8-dimethyl-n- (1-methylpiperidin-4-yl)-9h-pyrido[2, 3-b]indole-7-carboxamide and methods of use therefor
AU2009236380A1 (en)	2008-04-16	2009-10-22	Vertex Pharmaceuticals Incorporated	Inhibitors of phosphatidylinositol 3-kinase
KR20170060179A (ko)	2008-11-13	2017-05-31	길리아드 칼리스토가 엘엘씨	혈액 종양에 대한 요법
US8440677B2 (en)	2009-03-24	2013-05-14	Gilead Calistoga Llc	Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
AU2010239312A1 (en)	2009-04-20	2011-11-10	Gilead Calistoga Llc	Methods of treatment for solid tumors
EA036876B1 (ru)	2009-11-05	2020-12-30	Ризен Фармасьютикалз С.А.	Ингибиторы pi3k киназы
WO2012037155A2 (en) *	2010-09-13	2012-03-22	Gtx, Inc.	Tyrosine kinase inhibitors
BR112013027774B1 (pt) *	2011-05-04	2020-11-17	Rhizen Pharmaceuticals S.A.	composto e composição farmacêutica
DK2870157T3 (da) *	2012-07-04	2017-11-06	Rhizen Pharmaceuticals S A	Selektive pi3k delta-hæmmere

2013
- 2013-07-02 DK DK13744836.1T patent/DK2870157T3/da active
- 2013-07-02 CN CN201910154523.4A patent/CN109970742A/zh active Pending
- 2013-07-02 AP AP2015008207A patent/AP2015008207A0/xx unknown
- 2013-07-02 CN CN201380035108.8A patent/CN104470923B/zh active Active
- 2013-07-02 EA EA201492176A patent/EA028750B1/ru unknown
- 2013-07-02 WO PCT/IB2013/055434 patent/WO2014006572A1/en active Application Filing
- 2013-07-02 MY MYPI2014003647A patent/MY169987A/en unknown
- 2013-07-02 KR KR1020157001057A patent/KR101988079B1/ko active IP Right Grant
- 2013-07-02 SG SG10201704048UA patent/SG10201704048UA/en unknown
- 2013-07-02 RS RS20190687A patent/RS58793B1/sr unknown
- 2013-07-02 BR BR112014033055-7A patent/BR112014033055B1/pt active IP Right Grant
- 2013-07-02 CA CA2876995A patent/CA2876995C/en active Active
- 2013-07-02 MX MX2014015946A patent/MX357043B/es active IP Right Grant
- 2013-07-02 HU HUE13744836A patent/HUE034591T2/en unknown
- 2013-07-02 RS RS20171141A patent/RS56494B1/sr unknown
- 2013-07-02 LT LTEP17181585.5T patent/LT3260455T/lt unknown
- 2013-07-02 JP JP2015519472A patent/JP6181173B2/ja active Active
- 2013-07-02 PL PL13744836T patent/PL2870157T3/pl unknown
- 2013-07-02 EP EP13744836.1A patent/EP2870157B1/en active Active
- 2013-07-02 DK DK17181585.5T patent/DK3260455T3/da active
- 2013-07-02 SG SG11201408821SA patent/SG11201408821SA/en unknown
- 2013-07-02 ES ES13744836.1T patent/ES2647416T3/es active Active
- 2013-07-02 KR KR1020197015824A patent/KR102216606B1/ko active IP Right Grant
- 2013-07-02 PL PL17181585T patent/PL3260455T3/pl unknown
- 2013-07-02 PT PT137448361T patent/PT2870157T/pt unknown
- 2013-07-02 SI SI201331473T patent/SI3260455T1/sl unknown
- 2013-07-02 EP EP17181585.5A patent/EP3260455B1/en active Active
- 2013-07-02 AU AU2013285081A patent/AU2013285081B2/en not_active Ceased
- 2013-07-02 LT LTEP13744836.1T patent/LT2870157T/lt unknown
- 2013-07-02 SM SM20190334T patent/SMT201900334T1/it unknown
- 2013-07-02 SI SI201330819T patent/SI2870157T1/en unknown
- 2013-07-02 US US13/933,856 patent/US9150579B2/en active Active - Reinstated
- 2013-07-02 SM SM20170560T patent/SMT201700560T1/it unknown
- 2013-07-03 TW TW102123806A patent/TWI598100B/zh active
- 2013-07-05 AR ARP130102394 patent/AR091677A1/es not_active Application Discontinuation
2014
- 2014-12-18 ZA ZA2014/09329A patent/ZA201409329B/en unknown
- 2014-12-18 IL IL236351A patent/IL236351B/en active IP Right Grant
- 2014-12-22 PH PH12014502865A patent/PH12014502865B1/en unknown
- 2014-12-23 CL CL2014003511A patent/CL2014003511A1/es unknown
2015
- 2015-01-15 CO CO15007491A patent/CO7170166A2/es unknown
- 2015-08-21 US US14/832,962 patent/US9475818B2/en not_active Expired - Fee Related
- 2015-10-09 ZA ZA2015/07539A patent/ZA201507539B/en unknown
- 2015-10-27 HK HK15110550.4A patent/HK1209737A1/xx not_active IP Right Cessation
2016
- 2016-01-22 PH PH12016500156A patent/PH12016500156B1/en unknown
- 2016-10-03 US US15/283,515 patent/US9669033B2/en active Active
2017
- 2017-04-05 US US15/480,128 patent/US10072013B2/en active Active
- 2017-07-19 JP JP2017139758A patent/JP6416339B2/ja not_active Expired - Fee Related
- 2017-10-23 HR HRP20171610TT patent/HRP20171610T1/hr unknown
- 2017-11-10 CY CY20171101179T patent/CY1119588T1/el unknown
2018
- 2018-08-22 US US16/109,337 patent/US10570142B2/en active Active
2019
- 2019-06-03 CY CY20191100585T patent/CY1121793T1/el unknown
2020
- 2020-01-29 US US16/776,327 patent/US10981919B2/en active Active
2021
- 2021-04-01 US US17/220,806 patent/US20210403475A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR112014033055A2 (pt)	2017-06-27
EA028750B1 (ru)	2017-12-29
US20170020881A1 (en)	2017-01-26
KR20150036083A (ko)	2015-04-07
US20150361083A1 (en)	2015-12-17
US10570142B2 (en)	2020-02-25
US9669033B2 (en)	2017-06-06
KR102216606B1 (ko)	2021-02-17
PL3260455T3 (pl)	2019-12-31
CY1121793T1 (el)	2020-07-31
AP2015008207A0 (en)	2015-01-31
MX357043B (es)	2018-06-25
JP6416339B2 (ja)	2018-10-31
JP2015522009A (ja)	2015-08-03
KR101988079B1 (ko)	2019-06-11
EP2870157B1 (en)	2017-08-30
PT2870157T (pt)	2017-11-27
PH12014502865A1 (en)	2015-02-23
US20170204105A1 (en)	2017-07-20
MY169987A (en)	2019-06-19
AR091677A1 (es)	2015-02-18
TW201402123A (zh)	2014-01-16
PH12014502865B1 (en)	2015-02-23
CN109970742A (zh)	2019-07-05
CN104470923B (zh)	2019-03-29
SI3260455T1 (sl)	2019-07-31
US20210403475A1 (en)	2021-12-30
SG11201408821SA (en)	2015-01-29
LT2870157T (lt)	2017-12-11
EP3260455A1 (en)	2017-12-27
ES2647416T3 (es)	2017-12-21
SMT201700560T1 (it)	2018-01-11
RS56494B1 (sr)	2018-01-31
BR112014033055A8 (pt)	2021-09-08
EA201492176A1 (ru)	2015-08-31
HUE034591T2 (en)	2018-02-28
US10981919B2 (en)	2021-04-20
PH12016500156A1 (en)	2017-04-10
LT3260455T (lt)	2019-06-10
EP3260455B1 (en)	2019-03-20
US9475818B2 (en)	2016-10-25
CA2876995A1 (en)	2014-01-09
CA2876995C (en)	2020-10-06
US20200270258A1 (en)	2020-08-27
ZA201409329B (en)	2016-08-31
SG10201704048UA (en)	2017-06-29
US10072013B2 (en)	2018-09-11
CN104470923A (zh)	2015-03-25
CY1119588T1 (el)	2018-03-07
BR112014033055B1 (pt)	2023-01-31
US20190194206A1 (en)	2019-06-27
HRP20171610T1 (hr)	2018-03-23
TWI598100B (zh)	2017-09-11
EP2870157A1 (en)	2015-05-13
WO2014006572A1 (en)	2014-01-09
AU2013285081A1 (en)	2015-01-22
CL2014003511A1 (es)	2015-07-10
SMT201900334T1 (it)	2019-07-11
HK1209737A1 (en)	2016-04-08
IL236351B (en)	2018-01-31
AU2013285081B2 (en)	2017-01-12
MX2014015946A (es)	2015-07-17
JP2017186378A (ja)	2017-10-12
PH12016500156B1 (en)	2017-04-10
PL2870157T3 (pl)	2018-01-31
US9150579B2 (en)	2015-10-06
US20140011819A1 (en)	2014-01-09
ZA201507539B (en)	2017-01-25
IL236351A0 (en)	2015-02-26
SI2870157T1 (en)	2018-02-28
JP6181173B2 (ja)	2017-08-16
DK3260455T3 (da)	2019-06-11
CO7170166A2 (es)	2015-01-28
KR20190064687A (ko)	2019-06-10
DK2870157T3 (da)	2017-11-06

Publication	Publication Date	Title
IL284539A (en)	2021-08-31	Heterocycloamines as PI3K inhibitors
HK1209737A1 (en)	2016-04-08	Selective pi3k delta inhibitors pi3k
HK1211027A1 (en)	2016-05-13	Pyrrolotriazinone derivatives as pi3k inhibitors pi3k
SG10202003090VA (en)	2020-05-28	PI3K δ INHIBITOR
HK1248674B (zh)	2019-11-08	選擇性PI3Kδ抑制劑